Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL JAMES DOWNING

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1639159346
CMS profile
300554
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$626.73

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $626.73 20

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Sage Therapeutics, Inc. $325.00 5
Janssen Pharmaceuticals, Inc $104.32 4
Alkermes, Inc. $75.20 5
ITI, Inc. $39.20 2
AbbVie Inc. $37.62 2
Teva Pharmaceuticals USA, Inc. $26.15 1
Indivior Inc. $19.24 1

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL JAMES DOWNING

NPI 1639159346 · CMS profile ID 300554

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $626.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $32.6111/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102165 CMS
Teva Pharmaceuticals USA, Inc. $26.1511/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056789173 CMS
Alkermes, Inc. $13.9211/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808419 CMS
Indivior Inc. $19.2411/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034223069 CMS
Alkermes, Inc. $15.9609/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808417 CMS
Janssen Pharmaceuticals, Inc $24.9408/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102155 CMS
Alkermes, Inc. $14.7308/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808415 CMS
ITI, Inc. $25.5506/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040517805 CMS
Alkermes, Inc. $15.4206/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808413 CMS
Sage Therapeutics, Inc. $50.0006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017096065 CMS
Sage Therapeutics, Inc. $37.5006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017097227 CMS
Sage Therapeutics, Inc. $37.5006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017098319 CMS
Sage Therapeutics, Inc. $50.0006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017102035 CMS
Sage Therapeutics, Inc. $150.0006/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017104067 CMS
Janssen Pharmaceuticals, Inc $24.5105/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102187 CMS
ITI, Inc. $13.6504/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040517795 CMS
AbbVie Inc. $15.4203/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996737965 CMS
Alkermes, Inc. $15.1702/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808411 CMS
Janssen Pharmaceuticals, Inc $22.2602/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102175 CMS
AbbVie Inc. $22.2001/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996737959 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $327.48 15
PY2020 $163.49 9
PY2021 $551.28 27
PY2022 $399.89 22
PY2023 $626.73 20
PY2024 $647.99 23
PY2025 $847.36 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $914,450.61 88
PY2024 Recipient $2,949.66 2
PY2024 Principal investigator $1,362,460.91 98
PY2023 Recipient $59,611.81 14
PY2023 Principal investigator $997,596.68 181
PY2022 Principal investigator $897,046.39 115
PY2021 Principal investigator $714,455.57 113
PY2020 Principal investigator $1,352,717.69 219
PY2019 Recipient $157,177.13 20
PY2019 Principal investigator $1,373,636.72 268

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

288 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $5,900.85 12/31/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670118525
Principal investigator 1 Allergan Inc. $11,441.00 12/31/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670122911
Principal investigator 1 Allergan Inc. $4,524.50 12/31/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670123431
Principal investigator 1 Eisai Inc. $3,720.00 12/31/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549001
Principal investigator 1 Shire North American Group Inc $70.00 12/31/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE SPD503 IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 637716161
Recipient Supernus Pharmaceuticals, Inc. $14.71 12/30/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876781
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,214.94 12/20/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 699990487
Principal investigator 1 ACADIA Pharmaceuticals Inc $14,119.38 12/20/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 699990529
Principal investigator 1 Janssen Research & Development, LLC $7,597.00 12/20/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249213
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 12/19/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703924811
Principal investigator 1 Janssen Research & Development, LLC $2,641.50 12/19/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects with Treatment-resistant Depression No dispute reported 06/30/2026 654249215
Principal investigator 1 Allergan Inc. $700.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670114087
Principal investigator 1 Allergan Inc. $375.00 12/17/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670114161
Principal investigator 1 Allergan Inc. $500.00 12/17/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670114547
Principal investigator 1 Allergan Inc. $2,000.00 12/17/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670115525
Principal investigator 1 Eisai Inc. $1,600.00 12/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549005
Principal investigator 1 Eisai Inc. $1,600.00 12/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549007
Principal investigator 1 Eisai Inc. $1,824.00 12/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549009
Principal investigator 1 Eisai Inc. $1,600.00 12/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549011
Principal investigator 1 Eisai Inc. $1,600.00 12/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549013
Principal investigator 1 Eisai Inc. $1,600.00 12/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549015
Principal investigator 1 Eisai Inc. $2,084.00 12/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549017
Principal investigator 1 Eisai Inc. $3,117.00 12/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549019
Principal investigator 1 Eisai Inc. $4,121.00 12/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549021
Principal investigator 1 Janssen Research & Development, LLC $2,601.00 12/16/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249211
Recipient Supernus Pharmaceuticals, Inc. $6.10 12/16/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876779
Principal investigator 1 Allergan Inc. $12,858.25 12/13/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670110359
Principal investigator 1 Allergan Inc. $2,100.00 12/12/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670108835
Principal investigator 1 Allergan Inc. $800.00 12/12/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670108879
Principal investigator 1 Allergan Inc. $1,000.00 12/10/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670107619
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 12/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703925661
Principal investigator 1 Shire North American Group Inc $70.00 11/30/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE SPD503 IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 637715537
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $149.50 11/28/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685013223
Principal investigator 1 Eisai Inc. $2,319.00 11/26/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549029
Principal investigator 1 Eisai Inc. $3,870.00 11/26/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549031
Principal investigator 1 Eisai Inc. $1,166.00 11/26/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549033
Principal investigator 1 Eisai Inc. $2,319.00 11/26/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549035
Principal investigator 1 Janssen Research & Development, LLC $10,937.00 11/25/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249205
Principal investigator 1 Allergan Inc. $12,158.10 11/22/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670103323
Principal investigator 1 Boehringer Ingelheim International GmbH $48.16 11/21/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703924809
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,912.32 11/20/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 699990335
Principal investigator 1 ACADIA Pharmaceuticals Inc $9,156.24 11/20/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 699990363
Recipient Supernus Pharmaceuticals, Inc. $7.32 11/20/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876775
Recipient Supernus Pharmaceuticals, Inc. $2.84 11/20/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876777
Principal investigator 1 Allergan Inc. $9,852.45 11/13/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670096553
Recipient Supernus Pharmaceuticals, Inc. $7.29 11/08/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876773
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $287.50 11/06/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685013219
Principal investigator 1 Allergan Inc. $3,954.00 11/05/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670094803
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 11/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703922239
Principal investigator 1 Eisai Inc. $3,870.00 10/31/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549023
Principal investigator 1 Eisai Inc. $1,166.00 10/31/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549025
Principal investigator 1 Eisai Inc. $1,867.00 10/31/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549027
Principal investigator 1 Shire North American Group Inc $70.00 10/31/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE SPD503 IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 637714811
Principal investigator 1 Boehringer Ingelheim International GmbH $71.48 10/28/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703924807
Principal investigator 1 Shire North American Group Inc $25.00 10/28/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE SPD503 IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 637714775
Principal investigator 1 Shire North American Group Inc $75.00 10/28/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR, DOSE-OPTIMIZATION EVALUATION FOLLOWED BY A 1-YEAR OPEN-LABEL EVALUATION TO ASSESS THE SAFETY AND EFFICACY OF GUANFACINE HYDROCHLORIDE PROLONGED-RELEASE SPD503 IN CHILDREN AND ADOLESCENTS AGED 6 TO 17 YEARS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 637714777
Recipient Supernus Pharmaceuticals, Inc. $83.00 10/28/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876769
Recipient Supernus Pharmaceuticals, Inc. $40.50 10/28/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876771
Principal investigator 1 Janssen Research & Development, LLC $8,321.00 10/25/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249209
Principal investigator 1 Janssen Research & Development, LLC $1,386.00 10/24/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249207
Recipient Supernus Pharmaceuticals, Inc. $354.14 10/21/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876763
Recipient Supernus Pharmaceuticals, Inc. $137.18 10/21/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876765
Recipient Supernus Pharmaceuticals, Inc. $240.76 10/21/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876767
Principal investigator 1 Allergan Inc. $15,413.75 10/17/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670086223
Principal investigator 1 Allergan Inc. $9,630.15 10/15/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670085411
Principal investigator 1 Eisai Inc. $3,112.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548867
Principal investigator 1 Eisai Inc. $2,084.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548869
Principal investigator 1 Eisai Inc. $3,117.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548871
Principal investigator 1 Eisai Inc. $4,121.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548873
Principal investigator 1 Eisai Inc. $1,711.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548875
Principal investigator 1 Eisai Inc. $3,117.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548877
Principal investigator 1 Eisai Inc. $1,600.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548879
Principal investigator 1 Eisai Inc. $3,117.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548881
Principal investigator 1 Eisai Inc. $1,750.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548883
Principal investigator 1 Eisai Inc. $1,869.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548885
Principal investigator 1 Eisai Inc. $1,824.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548887
Principal investigator 1 Eisai Inc. $4,121.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548889
Principal investigator 1 Eisai Inc. $1,711.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548891
Principal investigator 1 Eisai Inc. $3,117.00 10/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548893
Principal investigator 1 Eisai Inc. $1,860.00 10/08/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549037
Principal investigator 1 Eisai Inc. $1,860.00 10/08/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549039
Recipient Supernus Pharmaceuticals, Inc. $500.96 10/08/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876759
Recipient Supernus Pharmaceuticals, Inc. $50.00 10/08/2019 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705876761
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 10/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703922759
Principal investigator 1 Boehringer Ingelheim International GmbH $12.50 10/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703922761
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703922807
Principal investigator 1 Eisai Inc. $1,867.00 10/01/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548865
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,385.50 09/30/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-042 No dispute reported 06/30/2026 699989937
Principal investigator 1 Janssen Research & Development, LLC $17,166.00 09/26/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249201
Principal investigator 1 Boehringer Ingelheim International GmbH $48.16 09/24/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703918827
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,530.79 09/23/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 699989863
Principal investigator 1 ACADIA Pharmaceuticals Inc $19,301.44 09/23/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 699989903
Principal investigator 1 Janssen Research & Development, LLC $4,826.00 09/23/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249197
Principal investigator 1 Boehringer Ingelheim International GmbH $606.87 09/19/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703925805
Principal investigator 1 Allergan Inc. $9,273.90 09/18/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670076523
Principal investigator 1 Boehringer Ingelheim International GmbH $609.30 09/18/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703925803
Principal investigator 1 Allergan Inc. $4,611.30 09/13/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670075319
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $287.50 09/11/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685010775
Principal investigator 1 Allergan Inc. $86.00 09/05/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670073373
Principal investigator 1 Allergan Inc. $86.00 09/03/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670071912
Principal investigator 1 Allergan Inc. $90.00 09/01/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670071449
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 09/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703920755
Principal investigator 1 Janssen Research & Development, LLC $8,278.00 08/26/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249203
Principal investigator 1 Allergan Inc. $14,511.25 08/23/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670068887
Principal investigator 1 Janssen Research & Development, LLC $10,881.00 08/23/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249199
Recipient Arbor Pharmaceuticals, Inc. $12,582.68 08/21/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658417
Principal investigator 1 Eisai Inc. $1,869.00 08/20/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548909
Principal investigator 1 Eisai Inc. $1,600.00 08/20/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548911
Principal investigator 1 Eisai Inc. $1,824.00 08/20/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548913
Principal investigator 1 Eisai Inc. $3,677.00 08/15/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548895
Principal investigator 1 Allergan Inc. $11,321.15 08/14/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670065177
Principal investigator 1 Allergan Inc. $45.00 08/01/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670062547
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703921073
Principal investigator 1 Allergan Inc. $3,791.45 07/30/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670061199
Principal investigator 1 Allergan Inc. $9,042.10 07/30/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670062013
Principal investigator 1 Janssen Research & Development, LLC $9,246.00 07/26/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249195
Principal investigator 1 Janssen Research & Development, LLC $13,028.00 07/25/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249191
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,521.50 07/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685010779
Principal investigator 1 Allergan Inc. $17,569.30 07/15/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670056817
Recipient Arbor Pharmaceuticals, Inc. $6,322.49 07/10/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658407
Principal investigator 1 Eisai Inc. $3,883.00 07/09/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548897
Principal investigator 1 Eisai Inc. $1,166.00 07/09/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548899
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $52,028.54 07/05/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER No dispute reported 06/30/2026 696054691
Principal investigator 1 Eisai Inc. $5,500.00 07/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548903
Principal investigator 1 Eisai Inc. $1,999.00 07/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548905
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 07/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703917765
Principal investigator 1 Janssen Research & Development, LLC $8,442.50 07/01/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249193
Principal investigator 1 Janssen Research & Development, LLC $11,019.00 06/27/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249189
Principal investigator 1 Allergan Inc. $8,922.40 06/25/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670053327
Principal investigator 1 Eisai Inc. $1,860.00 06/25/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548901
Principal investigator 1 Eisai Inc. $1,200.00 06/25/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548907
Principal investigator 1 Eisai Inc. $3,112.00 06/25/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548915
Principal investigator 1 Eisai Inc. $3,117.00 06/25/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548917
Principal investigator 1 Eisai Inc. $4,121.00 06/25/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548919
Principal investigator 1 Eisai Inc. $1,750.00 06/25/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548921
Principal investigator 1 Eli Lilly and Company $7,159.00 06/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-2 STUDY No dispute reported 06/30/2026 654290865
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,543.10 06/12/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685007701
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,641.55 06/10/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF SPN-812 ER FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705878673
Principal investigator 1 ACADIA Pharmaceuticals Inc $9,250.00 06/06/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-055 No dispute reported 06/30/2026 699989349
Principal investigator 1 ACADIA Pharmaceuticals Inc $9,250.00 06/06/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-059 No dispute reported 06/30/2026 699989369
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 06/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703912387
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,360.55 05/29/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685007699
Principal investigator 1 Allergan Inc. $11,419.00 05/28/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670047977
Principal investigator 1 Allergan Inc. $30,785.70 05/28/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670048231
Principal investigator 1 Janssen Research & Development, LLC $13,296.00 05/24/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249181
Principal investigator 1 Janssen Research & Development, LLC $8,890.00 05/24/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249187
Recipient Arbor Pharmaceuticals, Inc. $28,281.50 05/22/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658399
Principal investigator 1 Eisai Inc. $1,550.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548923
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548925
Principal investigator 1 Eisai Inc. $3,842.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548927
Principal investigator 1 Eisai Inc. $3,053.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548929
Principal investigator 1 Eisai Inc. $1,743.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548931
Principal investigator 1 Eisai Inc. $2,055.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548933
Principal investigator 1 Eisai Inc. $3,870.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548935
Principal investigator 1 Eisai Inc. $1,166.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548937
Principal investigator 1 Eisai Inc. $2,319.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548939
Principal investigator 1 Eisai Inc. $2,769.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548941
Principal investigator 1 Eisai Inc. $1,075.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548943
Principal investigator 1 Eisai Inc. $1,075.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548945
Principal investigator 1 Eisai Inc. $887.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548947
Principal investigator 1 Eisai Inc. $2,538.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548949
Principal investigator 1 Eisai Inc. $1,075.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548951
Principal investigator 1 Eisai Inc. $1,075.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548953
Principal investigator 1 Eisai Inc. $1,721.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548957
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548959
Principal investigator 1 Eisai Inc. $563.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548961
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548963
Principal investigator 1 Eisai Inc. $356.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548965
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548967
Principal investigator 1 Eisai Inc. $1,166.00 05/07/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548969
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 05/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703912187
Principal investigator 1 Allergan Inc. $18,106.05 04/25/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670040991
Principal investigator 1 Boehringer Ingelheim International GmbH $950.98 04/25/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703912357
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $3,046.24 04/25/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura No dispute reported 06/30/2026 701426079
Principal investigator 1 Allergan Inc. $8,391.35 04/23/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670039725
Principal investigator 1 Janssen Research & Development, LLC $22,860.00 04/22/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249183
Principal investigator 1 Janssen Research & Development, LLC $14,212.00 04/22/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249185
Recipient Arbor Pharmaceuticals, Inc. $26,348.73 04/17/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658391
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,066.55 04/17/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685007697
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,250.00 04/12/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training CCT No dispute reported 06/30/2026 704143189
Principal investigator 1 Eisai Inc. $1,500.00 04/11/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548997
Principal investigator 1 Eisai Inc. $1,860.00 04/11/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548999
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $234,708.34 04/10/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00014 No dispute reported 06/30/2026 696054023
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $85.70 04/09/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training CCT No dispute reported 06/30/2026 704143191
Principal investigator 1 Eisai Inc. $1,721.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548971
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548973
Principal investigator 1 Eisai Inc. $563.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548975
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548977
Principal investigator 1 Eisai Inc. $356.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548979
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548981
Principal investigator 1 Eisai Inc. $1,867.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548983
Principal investigator 1 Eisai Inc. $1,550.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548985
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548987
Principal investigator 1 Eisai Inc. $1,166.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548989
Principal investigator 1 Eisai Inc. $3,842.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548991
Principal investigator 1 Eisai Inc. $1,075.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548993
Principal investigator 1 Eisai Inc. $887.00 04/02/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548995
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 04/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703911627
Principal investigator 1 Boehringer Ingelheim International GmbH $1,392.89 03/28/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703925801
Principal investigator 1 Allergan Inc. $9,356.55 03/26/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670033727
Principal investigator 1 Allergan Inc. $5,389.35 03/26/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
PHASE IIA US POP W SOD 3125-201-002 No dispute reported 06/30/2026 670033877
Principal investigator 1 Boehringer Ingelheim International GmbH $1,556.46 03/26/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703925799
Principal investigator 1 Janssen Research & Development, LLC $2,298.00 03/25/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249163
Principal investigator 1 Janssen Research & Development, LLC $19,615.00 03/22/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249169
Principal investigator 1 Allergan Inc. $4,521.05 03/19/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670031261
Principal investigator 1 Supernus Pharmaceuticals, Inc. $5,251.14 03/14/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
EVALUATION OF SPN-812 ER 100 AND 200 MG EFFICACY AND SAFETY IN CHILDREN WITH ADHD - A DOUBLE-BLIND, PLACEBO- CONTROLLED, PIVOTAL TRIAL No dispute reported 06/30/2026 705878105
Principal investigator 1 Supernus Pharmaceuticals, Inc. $9,455.66 03/14/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
EVALUATION OF SPN-812 ER 200 AND 400 MG EFFICACY AND SAFETY IN ADOLESCENTS WITH ADHD - A DOUBLE-BLIND, PLACEBO-CONTROLLED, PIVOTAL TRIAL No dispute reported 06/30/2026 705878137
Principal investigator 1 Supernus Pharmaceuticals, Inc. $4,263.50 03/14/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF SPN-812 ER FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705878221
Principal investigator 1 Supernus Pharmaceuticals, Inc. $4,263.50 03/14/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF SPN-812 ER FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705878227
Principal investigator 1 Boehringer Ingelheim International GmbH $905.86 03/13/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703906767
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,332.50 03/13/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685006517
Recipient Arbor Pharmaceuticals, Inc. $90.00 03/12/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658383
Principal investigator 1 Eisai Inc. $26,386.02 03/12/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548859
Principal investigator 1 Eisai Inc. $2,055.00 03/12/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548861
Principal investigator 1 Eisai Inc. $1,550.00 03/12/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548863
Principal investigator 1 Eisai Inc. $209.13 03/12/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702549003
Principal investigator 1 Eli Lilly and Company $4,343.40 03/08/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 654296705
Principal investigator 1 Allergan Inc. $1,887.00 03/07/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670029489
Principal investigator 1 Allergan Inc. $9,500.00 03/07/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 670029521
Recipient Arbor Pharmaceuticals, Inc. $2,011.00 03/06/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658377
Principal investigator 1 Boehringer Ingelheim International GmbH $80.00 03/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703910919
Principal investigator 1 Boehringer Ingelheim International GmbH $12.50 03/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703910951
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 03/01/2019 Non-covered Recipient Entity
FutureSearch Trials of Dallas LP
Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 703910981
Principal investigator 1 Allergan Inc. $14,145.50 02/28/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670028101
Principal investigator 1 Janssen Research & Development, LLC $8,910.00 02/25/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249167
Recipient Arbor Pharmaceuticals, Inc. $68,381.95 02/22/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658369
Principal investigator 1 Janssen Research & Development, LLC $24,708.50 02/22/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249179
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,500.00 02/21/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
EVALUATION OF SPN-812 ER 200 AND 400 MG EFFICACY AND SAFETY IN ADOLESCENTS WITH ADHD - A DOUBLE-BLIND, PLACEBO-CONTROLLED, PIVOTAL TRIAL No dispute reported 06/30/2026 705877947
Principal investigator 1 Merck Sharp & Dohme Corporation $250.00 02/18/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 691314151
Principal investigator 1 Merck Sharp & Dohme Corporation $3,978.00 02/18/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 691314153
Principal investigator 1 Merck Sharp & Dohme Corporation $905.80 02/18/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 691314759
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,000.00 02/14/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-042 No dispute reported 06/30/2026 699988539
Principal investigator 1 Supernus Pharmaceuticals, Inc. $8,369.34 02/14/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
EVALUATION OF SPN-812 ER 100 AND 200 MG EFFICACY AND SAFETY IN CHILDREN WITH ADHD - A DOUBLE-BLIND, PLACEBO- CONTROLLED, PIVOTAL TRIAL No dispute reported 06/30/2026 705877819
Recipient Arbor Pharmaceuticals, Inc. $11,713.98 02/11/2019 Covered Recipient Physician Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate No dispute reported 06/30/2026 684658361
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,641.55 02/07/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF SPN-812 ER FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705877679
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,641.55 02/07/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF SPN-812 ER FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD No dispute reported 06/30/2026 705877685
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,443.40 02/07/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686168495
Principal investigator 1 Allergan Inc. $25,306.10 02/05/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670021509
Principal investigator 1 Supernus Pharmaceuticals, Inc. $3,499.52 02/04/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
EVALUATION OF SPN-812 ER 100 AND 200 MG EFFICACY AND SAFETY IN CHILDREN WITH ADHD - A DOUBLE-BLIND, PLACEBO- CONTROLLED, PIVOTAL TRIAL No dispute reported 06/30/2026 705877573
Principal investigator 1 ACADIA Pharmaceuticals Inc $21,788.45 02/01/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ACP-103-042 No dispute reported 06/30/2026 699988389
Principal investigator 1 Merck Sharp & Dohme Corporation $4,070.00 02/01/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 691325957
Principal investigator 1 Janssen Research & Development, LLC $9,186.00 01/25/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression No dispute reported 06/30/2026 654249165
Principal investigator 1 Janssen Research & Development, LLC $15,573.00 01/25/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249171
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/25/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249173
Principal investigator 1 Eisai Inc. $1,550.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548807
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548809
Principal investigator 1 Eisai Inc. $1,550.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548811
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548813
Principal investigator 1 Eisai Inc. $887.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548815
Principal investigator 1 Eisai Inc. $1,721.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548817
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548819
Principal investigator 1 Eisai Inc. $1,550.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548821
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548823
Principal investigator 1 Eisai Inc. $1,550.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548825
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548827
Principal investigator 1 Eisai Inc. $1,550.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548829
Principal investigator 1 Eisai Inc. $887.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548831
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548833
Principal investigator 1 Eisai Inc. $1,550.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548835
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548837
Principal investigator 1 Eisai Inc. $1,166.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548839
Principal investigator 1 Eisai Inc. $3,842.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548841
Principal investigator 1 Eisai Inc. $1,743.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548843
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548845
Principal investigator 1 Eisai Inc. $1,721.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548847
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548849
Principal investigator 1 Eisai Inc. $563.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548851
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548853
Principal investigator 1 Eisai Inc. $356.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548855
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548857
Principal investigator 1 Janssen Research & Development, LLC $29,233.50 01/24/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249177
Principal investigator 1 Janssen Research & Development, LLC $1,404.42 01/18/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation No dispute reported 06/30/2026 654249175
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $482.00 01/16/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685006515
Principal investigator 1 Allergan Inc. $13,729.40 01/03/2019 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670014237
Principal investigator 1 Eisai Inc. $1,550.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548781
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548783
Principal investigator 1 Eisai Inc. $1,166.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548785
Principal investigator 1 Eisai Inc. $3,842.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548787
Principal investigator 1 Eisai Inc. $3,053.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548789
Principal investigator 1 Eisai Inc. $887.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548791
Principal investigator 1 Eisai Inc. $1,721.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548793
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548795
Principal investigator 1 Eisai Inc. $563.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548797
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548799
Principal investigator 1 Eisai Inc. $356.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548801
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548803
Principal investigator 1 Eisai Inc. $3,677.00 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702548805
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,948.05 01/03/2019 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 685006519